Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBIT: 2015-2025

Historic EBIT for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$111.5 million.

  • Intellia Therapeutics' EBIT rose 23.00% to -$111.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of -$534.3 million for FY2024, which is 3.68% down from last year.
  • Latest data reveals that Intellia Therapeutics reported EBIT of -$111.5 million as of Q3 2025, which was down 1.35% from -$110.0 million recorded in Q2 2025.
  • Intellia Therapeutics' EBIT's 5-year high stood at -$46.4 million during Q1 2021, with a 5-year trough of -$144.8 million in Q3 2024.
  • Its 3-year average for EBIT is -$126.5 million, with a median of -$131.1 million in 2023.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 210.71% in 2022, then increased by 23.00% in 2025.
  • Intellia Therapeutics' EBIT (Quarterly) stood at -$80.4 million in 2021, then tumbled by 36.90% to -$110.1 million in 2022, then declined by 27.07% to -$139.9 million in 2023, then climbed by 2.46% to -$136.4 million in 2024, then rose by 23.00% to -$111.5 million in 2025.
  • Its EBIT was -$111.5 million in Q3 2025, compared to -$110.0 million in Q2 2025 and -$120.8 million in Q1 2025.